Tin tức & Phân tích

Tin tức ngành dược phẩm

Cập nhật chính sách, thị trường, và sự kiện quan trọng — được tổng hợp từ các nguồn uy tín quốc tế và trong nước.

📱 Nhận tin dược phẩm 3–5 lần/tuần qua WhatsApp Channel

23 bài viết

Ngành dượcBiopharma Dive13/05/2026

FDA chief Marty Makary resigns from agency, ending tumultuous tenure

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.

Ngành dượcFierce Pharma13/05/2026

BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey

Ngành dượcBiopharma Dive13/05/2026

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

Ngành dượcFierce Pharma13/05/2026

FDA Commissioner Marty Makary to resign, capping turbulent tenure: report

Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting criticism from all sides, according to reports.

Ngành dượcBiopharma Dive13/05/2026

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.

Ngành dượcFierce Pharma13/05/2026

Eli Lilly pauses Indian obesity awareness campaign after regulatory notices: report

Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules for prescription medicines, Reuters reports.

Ngành dượcFierce Pharma13/05/2026

Alkermes’ Lumryz hits phase 3 mark in another sleep disorder, fueling momentum from $2.4B Avadel acquisition

Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate drug Lumryz met all primary and key secondary endpoints in a rare sleep disorder.

Ngành dượcBiopharma Dive13/05/2026

A year after Vertex’s big launch, pain drug research faces a pivotal moment

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Ngành dượcFierce Pharma13/05/2026

Bayer's Eylea declines by 24%, bearing the brunt of biosmilar competition

After staving off significant sales declines for Eylea, Bayer is getting hit with full force by biosimilar competition for the eye disease treatment, which saw a 24% sales decline in the first quarter.

Ngành dượcFierce Pharma13/05/2026

Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu

The deal includes up to $320 million in future milestone payments plus tiered royalties on Veppanu sales, which will be split evenly between Arvinas and Pfizer.

Ngành dượcFierce Pharma13/05/2026

As public vaccine criticism quiets, RFK Jr. keeps safety inquiries running in background: NYT

Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the secretary of the Department of Health and Human Services is allegedly continuing his crusade in the background.

Ngành dượcFierce Pharma13/05/2026

EU advances scheme to bolster manufacturing autonomy, avert drug shortages

After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a new framework for the bloc focused on boosting supplies of critical medicines and navigating potential drug shortages.

Ngành dượcFierce Pharma13/05/2026

Bicara Therapeutics hires Replimune, Sanofi alum as chief commercial officer

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer.

Ngành dượcBiopharma Dive13/05/2026

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

Ngành dượcBiopharma Dive13/05/2026

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

Ngành dượcBiopharma Dive13/05/2026

Biotech layoffs are easing, but is the worst over?

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

Ngành dượcFierce Pharma13/05/2026

CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion. Additionally, the Australian company is writing off $5 billion in assets.

Ngành dượcFierce Pharma13/05/2026

Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer

With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot.

Ngành dượcFierce Pharma13/05/2026

Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan

Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five oncology player by 2035, plus a major $1.3 billion cost optimization initiative.

Ngành dượcBiopharma Dive13/05/2026

Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.